Key result
Third-generation oral contraceptives linked to ~100% higher VTE risk than second-generation, likely explained by bias.
Why the study?
Empirical evidence on bias or systematic error influencing the association between third-generation oral contraceptives and venous thromboembolism risk required review to distinguish causality from bias.
Do third-generation oral contraceptives increase the risk of venous thromboembolism compared to second-generation oral contraceptives?
Do third-generation oral contraceptives increase the risk of venous thromboembolism compared to second-generation oral contraceptives?
The apparent increased risk of venous thromboembolism with third-generation oral contraceptives is likely due to bias rather than a causal relationship, and the absolute risk of adverse cardiovascular outcomes remains extremely low.
Late in 1995 and early 1996, 4 epidemiologic studies were published that resulted in a crude mean weighted relative risk of approximately 2 when third-generation oral contraceptives were compared with second-generation oral contraceptives as risk factors for venous thromboembolism. This article reviews empirical evidence on bias or systematic error that may have influenced the estimates of association. The Bradford-Hill criteria to distinguish causality from an observed association were used to consider whether third-generation oral contraceptives cause an apparent excess in the occurrence of venous thromboembolism. Bias is more likely than a causal relationship to explain the associations observed for venous thromboembolism. For myocardial infarction, bias may mask the full benefit of third-generation oral contraceptives. For stroke, the question of causality is moot because statistically significant differences between third- and second-generation products have not been detected. The clinical importance and the public health significance of any differences among the various products with respect to adverse cardiovascular outcomes are trivial and undetectable because of the extremely low incidence of those disorders among users of oral contraceptives. The oral contraceptive pill is 99.9% effective when used correctly. All oral contraceptives on the market are safe and getting safer.
No takes yet. Share an insight, caveat, or question.
Walter O. Spitzer (1998) conducted a review in Venous thromboembolism. Third-generation oral contraceptives vs. Second-generation oral contraceptives was evaluated on Venous thromboembolism (RR ~2). Third-generation oral contraceptives were associated with a relative risk of approximately 2 for venous thromboembolism compared with second-generation products, which is likely explained by bias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: